Baidu
map

JACC: 坚持他汀和降压治疗,减少致死性卒中的发生

2016-07-11 MedSci MedSci原创

背景:坚持药物治疗方案的依从性差是常见的,可能有助于相关疾病的发生。目标:研究者旨在评估不坚持他汀类和/或抗高血压治疗与致命性卒中的风险的相关性。方法:研究者使用1995至2007年芬兰国家登记中的电子医疗和处方记录进行一项以人口为基础的研究。58266例高胆固醇血症的患者,年龄30岁以上,无卒中或心血管疾病。在平均随访5.5年中,532例死于脑卒中和57734例无卒中事件(对照组)。研究者获得两

背景:坚持药物治疗方案的依从性差是常见的,可能有助于相关疾病的发生。

目标:研究者旨在评估不坚持他汀类和/或抗高血压治疗与致命性卒中的风险的相关性。

方法:研究者使用1995至2007年芬兰国家登记中的电子医疗和处方记录进行一项以人口为基础的研究。58266例高胆固醇血症的患者,年龄30岁以上,无卒中或心血管疾病。在平均随访5.5年中,532例死于脑卒中和57734例无卒中事件(对照组)。研究者获得两研究组坚持他汀类药物和降压治疗的依从性,并且估计依从性不好,脑卒中死亡的风险。

结果:在所有的高胆固醇血症患者,与他汀治疗依从良好的患者相比,调整后的比值比为非贴壁的他汀类药物依从不好的患者卒中死亡或随访结束4年前的校正OR值为1.35(95%CI:1.04-1.74),在脑卒中死亡或随访结束那年的校正OR为2.04(95%CI:1.72-2.43)。高胆固醇血症且高血压患者,与那些坚持他汀类药物和降压治疗的患者相比,那些不坚持他汀和降压治疗的患者卒中死亡的OR为7.43(95%CI:5.22-10.59),那些不坚持对他汀类药物治疗和但坚持降压治疗患者卒中死亡的OR为1.82(95%CI:1.43至2.33),那些坚持他汀治疗但未坚持降压治疗的患者卒中死亡的OR为1.30(95%CI:0.53至3.20)。

结论:高胆固醇血症和高血压患者不服用他汀类药物和抗高血压药物,发生致命性卒中的风险增加。如果病人是坚持其中一种疗法,致死性卒中发生的风险是降低。

原始出处:

Herttua K, Martikainen P, et al. Poor Adherence to Statin and Antihypertensive Therapies as Risk Factors for Fatal Stroke. J Am Coll Cardiol. 2016 Apr 5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853549, encodeId=4e32185354928, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 18 11:33:00 CST 2016, time=2016-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145795, encodeId=d91d145e956e, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:05:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291876, encodeId=123712918e640, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325265, encodeId=b2121325265d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360859, encodeId=8986136085924, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568248, encodeId=c86415682484b, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
    2016-08-18 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853549, encodeId=4e32185354928, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 18 11:33:00 CST 2016, time=2016-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145795, encodeId=d91d145e956e, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:05:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291876, encodeId=123712918e640, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325265, encodeId=b2121325265d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360859, encodeId=8986136085924, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568248, encodeId=c86415682484b, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
    2016-10-11 ylzr123

    好文值得点赞!继续关注学习。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1853549, encodeId=4e32185354928, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 18 11:33:00 CST 2016, time=2016-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145795, encodeId=d91d145e956e, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:05:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291876, encodeId=123712918e640, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325265, encodeId=b2121325265d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360859, encodeId=8986136085924, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568248, encodeId=c86415682484b, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853549, encodeId=4e32185354928, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 18 11:33:00 CST 2016, time=2016-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145795, encodeId=d91d145e956e, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:05:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291876, encodeId=123712918e640, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325265, encodeId=b2121325265d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360859, encodeId=8986136085924, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568248, encodeId=c86415682484b, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853549, encodeId=4e32185354928, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 18 11:33:00 CST 2016, time=2016-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145795, encodeId=d91d145e956e, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:05:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291876, encodeId=123712918e640, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325265, encodeId=b2121325265d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360859, encodeId=8986136085924, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568248, encodeId=c86415682484b, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1853549, encodeId=4e32185354928, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 18 11:33:00 CST 2016, time=2016-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145795, encodeId=d91d145e956e, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:05:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291876, encodeId=123712918e640, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325265, encodeId=b2121325265d0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360859, encodeId=8986136085924, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568248, encodeId=c86415682484b, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Jul 13 14:33:00 CST 2016, time=2016-07-13, status=1, ipAttribution=)]

相关资讯

治疗糖尿病,不要忘记使用他汀

对于糖尿病患者,不应仅仅关注降糖。动脉粥样硬化性心血管疾病(如冠心病、心肌梗死与脑梗死等)是糖尿病患者致死致残的主要原因,有效防治大血管病变才是治疗糖尿病的最终目标。为达此目的,一方面要合理的控制血糖,同时要积极控制血压并根据患者具体情况应用他汀降低胆固醇水平。哪些糖尿病患者需要接受他汀治疗?所有确诊动脉粥样硬化性心血管疾病(冠心病、缺血性卒中、外周动脉疾病[如预动脉或下肢动脉狭窄超过50%]等)

JAHA:刷新旧观念 你可以做个健康的胖子

6月3日在线发表于《美国心脏协会杂志》(JAHA)的一项人口研究,评估了英国3682名无代谢障碍和3597名有代谢障碍的受试者的C反应蛋白(CRP)水平,随访近11年,发现代谢良好的肥胖患者心血管风险似乎很低,这些无代谢综合征的肥胖患者,CRP水平与非肥胖的代谢健康者相似。所有受试者中,随着符合代谢综合征诊断标准的条件数量增加,CRP水平也增加,而且腹部肥胖者的CRP水平较高。在这项研究中,若受试

JAMA Intern Med:心脏病患者,低密度脂蛋白水平并不是越低越好

背景:国际指南推荐患有缺血性心脏病的患者进行他汀类药物治疗预防心血管事件的发生,但他汀治疗的目标低密度脂蛋白胆固醇(LDL-C)值不同。这个问题相关的试验数据不确定,缺乏观测数据。目的:评估缺血性心脏病患者应用他汀治疗的LDL-C水平与心血管事件发生的相关性。设计、设置和参与者:这项研究是基于人口的观察性队列研究,从2009年到2013年,应用来自以色列的医疗保健机构数据,这个机构超过430万名成

J Stroke Cerebrovasc Dis:他汀药物可降低缺血性卒中感染发生的风险

目标:他汀类药物独立于其降脂作用具有免疫调节的作用和外周抗炎的特性。在临床研究中,这些性质是否降低卒中后感染风险尚不确定。研究者评估18岁以上住院的缺血性卒中患者,他汀类暴露对卒中后感染发生的风险。材料与方法:对急性护理医院电子病历进行回顾性分析。将患者分配到暴露队列,感染前应用他汀类药物,应用他汀药物治疗但未感染。未暴露队列包括未应用他汀类药物,或感染后应用他汀类药物。校正卒中后感染的危险因素条

Breast Cancer Res:福音!他汀类药物或可有效治疗雌激素受体阳性的乳腺癌女性

近日,来自伦敦大学癌症研究学院的研究人员发现,乳腺癌细胞产生一种模仿雌激素的分子,因此他们呼吁进行临床试验以探究他汀类药物对复发性乳腺癌患者的治疗效果,该研究成果已发表于Breast Cancer Research。在英国,每年有多达4万名女性诊断为雌激素受体(ER)阳性乳腺癌,很多患者术后服用他莫昔芬或芳香酶抑制剂来阻断雌激素的作用,并降低疾病的复发风险。但是,即使是经过内分泌治疗仍有约1.2 

BMJ:重视媒体报道的健康事件对民众医疗健康相关行为的影响

本研究旨在评估激烈的他汀药物治疗的利弊争议的媒体报道对他汀药物使用的影响。前瞻性收集初级保健的电子数据以进行中断时间序列分析。纳入2011年1月至2015年3月每个月新服用或目前正在服用他汀类药物治疗原发性和继发性心血管疾病的患者。主要研究结果为媒体报道后开始/停止服用他汀类药物的校正后的比值比。结果发现,尽管有记录风险评分的患者总体比例下降,但是并没有证据表明高密度媒体报道时期与心血管疾病风险得

Baidu
map
Baidu
map
Baidu
map